Rifaximin in Pregnancy: Safety and Use
Rifaximin should generally be avoided during pregnancy due to demonstrated teratogenic effects in animal studies, though it may be considered when clinically essential for life-threatening maternal conditions where benefits clearly outweigh fetal risks. 1
FDA Pregnancy Classification and Animal Data
The FDA label explicitly states there are no available data on rifaximin use in pregnant women to inform drug-associated risks 1. However, animal reproduction studies reveal concerning findings:
- Teratogenic effects in rats at doses 0.9-5 times human doses (150-300 mg/kg)
- Teratogenic effects in rabbits at doses 0.7-33 times human doses (62.5-1,000 mg/kg)
- Specific malformations observed: cleft palate, agnathia, jaw shortening, hemorrhage, ocular abnormalities (eyes partially open, small eyes), brachygnathia, incomplete ossification, and increased thoracolumbar vertebrae 1
These teratogenic effects occurred at doses that also caused reduced maternal body weight gain, suggesting maternal toxicity may contribute to fetal harm.
Clinical Context and Guideline Perspective
The 2023 EASL guidelines on liver diseases in pregnancy do not include rifaximin in their comprehensive medication compatibility table 2, which notably lists numerous other antibiotics and hepatic medications with pregnancy safety data. This omission is telling—if rifaximin were considered safe or had adequate human data, it would likely be included.
When Rifaximin Might Be Considered
Despite the concerning animal data, rifaximin has theoretical advantages in pregnancy due to its minimal systemic absorption (virtually nonabsorbable from the GI tract) 3, 4. This pharmacologic property means:
- High intraluminal drug concentrations with minimal maternal systemic exposure
- Theoretically lower fetal exposure compared to systemically absorbed antibiotics
- Excellent safety profile in non-pregnant populations
Clinical scenarios where use might be justified:
- Life-threatening hepatic encephalopathy in pregnant women with advanced liver disease where maternal mortality risk is high
- Severe infectious diarrhea in pregnancy where fluoroquinolones are contraindicated and maternal dehydration/sepsis poses immediate risk 3
- Small intestinal bacterial overgrowth causing severe malnutrition threatening maternal-fetal health
Critical Decision-Making Algorithm
Step 1: Assess maternal condition severity
- Is this immediately life-threatening?
- Are there safer alternatives with human pregnancy data?
Step 2: Consider trimester
- First trimester (organogenesis): Avoid unless life-threatening—highest teratogenic risk period
- Second/third trimester: Use only if essential—organogenesis complete but growth effects possible
Step 3: Informed consent
- Advise pregnant women of potential fetal risk as mandated by FDA labeling 1
- Document risk-benefit discussion thoroughly
Step 4: If used, implement monitoring
- Fetal ultrasound for structural abnormalities
- Growth monitoring throughout pregnancy
Important Caveats
- The animal teratogenicity data cannot be dismissed—these were consistent findings across two species at clinically relevant dose multiples
- Lack of human data does not equal safety; it reflects insufficient study
- One older rat fertility study (1986) showed no adverse effects up to 100 mg/kg 5, but this does not address teratogenicity during organogenesis
- The suggestion that rifaximin "should be useful in treating hosts such as pregnant women" 3 is theoretical speculation from 2005, not evidence-based recommendation
Breastfeeding Considerations
No information exists regarding rifaximin presence in human milk, effects on breastfed infants, or milk production 1. Given minimal systemic absorption, theoretical risk to nursing infants is low, but this remains unproven.
The clinical need for rifaximin must be weighed against unknown risks to the breastfed infant, with consideration of alternative feeding options if treatment is essential.